Industry News

Non-Viral Gene Delivery Technology European Patent Awarded

Published in Gene Therapy Weekly, July 13th, 2000

Transgene (TRGNY), Strasbourg, France, announced that it has been issued European patent 901,463 entitled "Glycerolipid compounds useful for transferring active substances into target cells" covering the use of the company's pcTG90 cationic lipid based non-viral system for the delivery of genes into cells."

pcTG90 is a newly designed cationic glycerolipid that binds with plasmid DNA and can efficiently deliver genes to target organs in vivo. In addition to its efficiency, this synthetic vector is attractive because it is easily manipulated and is less likely to cause the patient's immune system to mount an immune response to it than vectors containing protein...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-07-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry